Skip to content

Metabononics disparity study of blood from different sites in liver cirrhosis individuals

Clinical studies of alternations of human internal environment and risk prediction of adverse events subsequent to transjugular intrahepatic portosystemic shunt in liver cirrhosis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000039614
Enrollment
Unknown
Registered
2020-11-03
Start date
2020-11-09
Completion date
Unknown
Last updated
2021-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cirrhosis

Interventions

Liver cirrhosis group vs healthy control group:Nil

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 18-75 years; 2. Patients diagnosed with cirrhosis; 3. Patients undergoing elective TIPS.

Exclusion criteria

Exclusion criteria: 1. Patients who had undergone tips or surgical shunt in the past; 2. Patients with previous history of hepatic encephalopathy, or diagnosed with hepatic encephalopathy at the time of inclusion; 3. Subjects with Hepatic myelopathy and other neuropsychiatric diseases; 4. Those patients who used nutrition, antibiotics or lactulose within 4 weeks before operation; 5. Patients with uncontrollable or stable cirrhotic complications such as gastrointestinal bleeding, spontaneous peritonitis, hepatorenal syndrome and hepatopulmonary syndrome less than 1 week; 6. Patients with heart, lung, kidney, brain and other major organ dysfunction; 7. Those subjects whose vision impairment affects reading; 8. People with very low education level can't read and write simple words; 9. Subjects from high altitude (> 2500 m); 10. Pregnant and lactating women; 11. For the subjects with child score more than 12, transaminase was 5 times higher than the upper limit of normal 12. Patients with cholestatic liver disease (primary biliary cholangitis, primary sclerosing cholangitis and extrahepatic bile duct obstruction, etc.); 13. Patients with malignant tumor; 14. Patients with cavernous transformation of the portal vein.

Design outcomes

Primary

MeasureTime frame
Metabonomics;

Countries

China

Contacts

Public ContactHuan Tong

West China Hospital of Sichuan University

doctortonghuan@163.com+86 28-85423387

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026